ProCE Banner Activity

CAPTIVATE MRD Cohort: 2-Yr Postrandomization Efficacy and Safety With First-Line Ibrutinib + Venetoclax in CLL

Slideset Download
Conference Coverage
Initial therapy with ibrutinib + venetoclax for 12 cycles resulted in a 2-year DFS rate of 95.3% in patients with undetectable MRD who were subsequently randomized to placebo and 100% in those subsequently randomized to ibrutinib.

Released: December 21, 2021

Expiration: December 20, 2022

No longer available for credit.
Begin Activity


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from



Daiichi Sankyo, Inc.


Incyte Corporation

Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp

Novartis Pharmaceuticals Corporation